BIO Stock — Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (BIO)

Updated October 16, 2026.

BIO is a Stock. Total return is 13790.7% over the past 46.6 years.

Bio-Rad Laboratories develops, manufactures, and distributes life science research instruments, reagents, and consumables, along with clinical diagnostic test systems and software for laboratories, hospitals, pharmaceutical companies, and biotechnology firms worldwide. The company operates through two segments: Life Science, which serves research and biopharmaceutical environments, and Clinical Diagnostics, which provides testing systems for clinical and hospital laboratories. Bio-Rad does not currently have an established dividend distribution schedule.

BIO performance

Price and return data through 2026-10-16.

Total return is 13790.7% over the past 46.6 years. Over the past year its total return — price change plus distributions reinvested — is 13.2%. Its deepest 1-year drawdown was 28.9%.

BIO key facts

Asset type

Stock

Asset class

Equity

Inception date

02/27/1980

Distribution frequency

None

Last close

$353.70 (as of 2026-10-16)

Market cap

$7,667,203,357

Average volume

207686.0

Beta

1.068

Payout ratio

0.0%

P/E ratio

44.83

Forward P/E

41.3223

EPS

$7.89

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIO risks and drawbacks

The deepest 1-year drawdown on record here is 28.9%.

Who may consider BIO — and who may not

It is a weaker fit for investors who need monthly cash flow (BIO does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BIO

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions